On Wednesday, Biogen Inc BIIB reported third-quarter adjusted EPS of $4.08, down 6%, beating the consensus of $3.79.
The corporate reported gross sales of $2.47 billion, down 3% yr over on fixed forex and reported foundation, beating the consensus of $2.43 billion.
A number of sclerosis income of $1.05 billion decreased by 9% (down 9% on fixed forex). The a number of sclerosis drug Tysabri gross sales have been right down to $406.1 million from $456.3 million.
Additionally Learn: Biogen Terminates Collaboration With Sage Therapeutics For Neurological Dysfunction Candidate
Uncommon illness income elevated 10% yr over yr (up 10% CC) to $495 million.
Spinraza’s income fell to $381.4 million from $448.2 million a yr in the past.
Revenues from Skyclarys, acquired through Reata acquisition, reached $102.3 million through the quarter.
In Alzheimer’s illness, Biogen mentioned Leqembi third quarter world in-market gross sales of roughly $67 million, together with U.S. in-market gross sales of roughly $39 million; E.U. CHMP re-examination anticipated to be accomplished this yr.
Postpartum melancholy drug Zurzuvae’s third-quarter gross sales reached $22 million.
Steering: Biogen raised its 2024 adjusted EPS steering to $16.10-$16.60 versus prior steering of $15.75-$16.25 and consensus of $16.19.
Biogen continues to count on 2024 income to say no by a low-single-digit proportion, with core pharmaceutical income to be comparatively flat in comparison with 2023, as additional declines in a number of sclerosis product revenues are anticipated to be offset by will increase in income from new product launches.
For 2024 in comparison with 2023, Biogen expects working revenue to develop at a high-teen proportion with mid-single digit proportion level working margin enchancment.
Worth Motion: BIIB inventory is down 1.37% at $180.95 on the final verify on Wednesday.
Additionally Learn:
Market Information and Knowledge delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
